Merit Financial Group LLC Buys 7,125 Shares of Thermo Fisher Scientific Inc. $TMO

Merit Financial Group LLC boosted its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 47.9% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 21,997 shares of the medical research company’s stock after acquiring an additional 7,125 shares during the quarter. Merit Financial Group LLC’s holdings in Thermo Fisher Scientific were worth $11,028,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of TMO. North Dakota State Investment Board bought a new stake in Thermo Fisher Scientific in the fourth quarter worth $7,505,000. Boston Trust Walden Corp increased its holdings in shares of Thermo Fisher Scientific by 9.7% in the fourth quarter. Boston Trust Walden Corp now owns 43,973 shares of the medical research company’s stock worth $25,480,000 after buying an additional 3,873 shares during the period. Xponance LLC lifted its stake in shares of Thermo Fisher Scientific by 8.1% in the 4th quarter. Xponance LLC now owns 59,295 shares of the medical research company’s stock valued at $34,358,000 after acquiring an additional 4,436 shares during the last quarter. Hudson Value Partners LLC grew its position in Thermo Fisher Scientific by 24.9% during the 2nd quarter. Hudson Value Partners LLC now owns 16,653 shares of the medical research company’s stock worth $8,349,000 after acquiring an additional 3,317 shares during the last quarter. Finally, Sandro Wealth Management LLC purchased a new position in Thermo Fisher Scientific in the 4th quarter worth approximately $2,089,000. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the stock. HSBC cut shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating and cut their target price for the stock from $670.00 to $540.00 in a report on Wednesday, June 3rd. Wall Street Zen upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Saturday, August 1st. Weiss Ratings upgraded shares of Thermo Fisher Scientific from a “hold (c-)” rating to a “hold (c)” rating in a report on Tuesday, July 14th. Sanford C. Bernstein assumed coverage on Thermo Fisher Scientific in a report on Friday, June 26th. They set a “market perform” rating and a $520.00 price target on the stock. Finally, Evercore set a $570.00 price objective on Thermo Fisher Scientific in a report on Monday, July 6th. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $619.41.

Insider Activity

In other news, VP Lisa P. Britt sold 5,850 shares of the company’s stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $580.00, for a total value of $3,393,000.00. Following the sale, the vice president directly owned 14,784 shares of the company’s stock, valued at $8,574,720. This represents a 28.35% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Michael D. Shafer sold 25,500 shares of Thermo Fisher Scientific stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $600.00, for a total transaction of $15,300,000.00. Following the transaction, the executive vice president directly owned 20,994 shares of the company’s stock, valued at approximately $12,596,400. This trade represents a 54.85% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 52,053 shares of company stock worth $30,643,589. 0.33% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Price Performance

Shares of NYSE TMO opened at $588.17 on Monday. Thermo Fisher Scientific Inc. has a 1 year low of $435.27 and a 1 year high of $643.99. The stock has a market capitalization of $217.48 billion, a P/E ratio of 31.64, a P/E/G ratio of 2.39 and a beta of 0.84. The company’s 50-day moving average is $529.37 and its 200 day moving average is $508.75. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.55 and a quick ratio of 1.18.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, beating the consensus estimate of $5.71 by $0.32. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The business had revenue of $11.99 billion for the quarter, compared to analysts’ expectations of $11.71 billion. During the same period in the previous year, the firm posted $4.28 EPS. The business’s revenue was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. On average, sell-side analysts expect that Thermo Fisher Scientific Inc. will post 25.12 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be issued a $0.47 dividend. The ex-dividend date is Tuesday, September 15th. This represents a $1.88 dividend on an annualized basis and a yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio is 10.11%.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.